- Home
- CYRX vs MREO Comparison
CYRX vs MREO Comparison
Compare CYRX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- MREO
- Stock Information
- Founded
- CYRX 1999
- MREO 2015
- Country
- CYRX United States
- MREO United Kingdom
- Employees
- CYRX N/A
- MREO N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- MREO Health Care
- Exchange
- CYRX Nasdaq
- MREO Nasdaq
- Market Cap
- CYRX 438.7M
- MREO 281.6M
- IPO Year
- CYRX N/A
- MREO N/A
- Fundamental
- Price
- CYRX $8.61
- MREO $1.78
- Analyst Decision
- CYRX Strong Buy
- MREO Strong Buy
- Analyst Count
- CYRX 10
- MREO 5
- Target Price
- CYRX $11.70
- MREO $7.40
- AVG Volume (30 Days)
- CYRX 572.3K
- MREO 935.5K
- Earning Date
- CYRX 11-06-2025
- MREO 11-11-2025
- Dividend Yield
- CYRX N/A
- MREO N/A
- EPS Growth
- CYRX N/A
- MREO N/A
- EPS
- CYRX 1.35
- MREO N/A
- Revenue
- CYRX $237,879,000.00
- MREO $500,000.00
- Revenue This Year
- CYRX N/A
- MREO N/A
- Revenue Next Year
- CYRX $9.08
- MREO $55.50
- P/E Ratio
- CYRX $6.43
- MREO N/A
- Revenue Growth
- CYRX 24.93
- MREO N/A
- 52 Week Low
- CYRX $4.58
- MREO $1.47
- 52 Week High
- CYRX $10.46
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- CYRX 48.55
- MREO 49.51
- Support Level
- CYRX $8.53
- MREO $1.68
- Resistance Level
- CYRX $10.46
- MREO $1.88
- Average True Range (ATR)
- CYRX 0.56
- MREO 0.07
- MACD
- CYRX -0.08
- MREO 0.02
- Stochastic Oscillator
- CYRX 24.25
- MREO 50.00
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).